eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2024
vol. 19
 
Share:
Send email
Share:
Review paper

Investigation of the expression level of methylated septin 9 gene and serological carcinoembryonic antigen to diagnose colorectal cancer. A meta-analysis study

Sharifeh Jorboniyan
1
,
Haniyeh Bashi Zadeh Fakhar
2
,
Mohammad-Esmaiel Akbari
2
,
Neda Izadi
3
,
Shaghayegh Rangraz
4

  1. Department of Laboratory Science, Chalous Branch, Islamic Azad University, Chalous, Iran
  2. Cancer Research Centre (CRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. Research Center for Social Determinants of Health, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. Department of Medical Science, Islamic Azad University, Chalus Branch, Chalous, Iran
Gastroenterology Rev 2024; 19 (4): 368–379
DOI: https://doi.org/10.5114/pg.2024.145381
Online publish date: 2024/12/02
Article file
- Investigation of the expression (1).pdf  [0.14 MB]
Get citation
 
PlumX metrics:
 
1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Rev 2019; 14: 89-103.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49.
3. Ma H, Brosens LA, Offerhaus GJ, et al. Pathology and genetics of hereditary colorectal cancer. Pathology 2018; 50: 49-59.
4. Safiri S, Sepanlou SG, Ikuta KS, et al. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 2019; 4: 913-33.
5. Goshayeshi L, Ghaffarzadegan K, Khooei A, et al. Prevalence and clinicopathological characteristics of mismatch repair-deficient colorectal carcinoma in early onset cases as compared with late-onset cases: a retrospective cross-sectional study in Northeastern Iran. BMJ Open 2018; 8: e023102.
6. Hoseini B, Rahmatinejad Z, Goshayeshi L, et al. Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry. BMC Cancer 2022; 22: 48.
7. Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in Iran: a review. Arch Iran Med 2009; 12: 161-9.
8. Maraqa B, Al-Shbool G, Abu-Shawer O, et al. Frequency of mismatch repair protein (MMRP) deficiency among young jordanians diagnosed with colorectal carcinoma (CRC). Gastroenterol Res Pract 2020; 2020: 5632984.
9. Coppede, F. Epigenetic biomarkers of colorectal cancer: focus on DNA methylation. Cancer Lett 2014; 342: 238-47.
10. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 2015; 149: 1204-25.e1212.
11. Arellano ML, García-Arranz M, Ruiz R, et al. A first step to a biomarker of curative surgery in colorectal cancer by liquid biopsy of methylated septin 9 gene. Dis Markers 2020; 2020: 9761406.
12. Arellano ML, García-Arranz M, Guadalajara H, et al. Analysis of septin 9 gene hypermethylation as follow-up biomarker of colorectal cancer patients after curative surgery. Diagnostics (Basel) 2022; 12: 993.
13. Bénard F, Barkun AN, Martel M, von Renteln D. Systematic review of colorectal cancer screening guidelines for average-risk adults: summarizing the current global recommendations. World J Gastroenterol 2018; 24: 124-38.
14. Ramezani S, Parkhideh R, Bhattacharya K. Beyond colonoscopy: exploring new cell surface biomarkers for detection of early, heterogenous colorectal lesions. Front Oncol 2021; 5: 251-60.
15. Roth JA, deVos T, Ramsey SD. Clinical and budget impact of increasing colorectal cancer screening by blood- and stool-based testing. Am Health Drug Benefits 2019; 12: 256-62.
16. Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol 2014; 14: 183.
17. Sun J, Fei F, Zhang M, et al. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer 2019; 19: 450-5.
18. Liu XC, Dai YL, Huang F, et al. Diagnostic value of carcinoembryonic antigen combined with multi-inflammatory cell ratios in colorectal cancer. Dis Markers 2022; 2022: 4889616.
19. Li X, Guo D, Chu L, et al. Potential diagnostic value of combining inflammatory cell ratios with carcinoembryonic antigen for colorectal cancer. Cancer Manag Res 2019; 11: 9631-40.
20. Yang X, Xu ZJ, Chen X, et al. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. World J Gastroenterol 2019; 25: 2099-109.
21. Higgins JPT, Thomas J, Chandler J, et al. (eds.). Cochrane handbook for systematic reviews of interventions. 2nd ed. John Wiley & Sons, Chichester, UK 2019; 12: 150-61.
22. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P). Syst Rev 2015; 4: 1-6.
23. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. Br Med J 2020; 14: 357-68.
24. Vyncke V, De Clercq B, Stevens V, et al. Does neighborhood social capital aid in levelling the social gradient in the health and well-being of children and adolescents? A literature review. BMC Public Health 2013; 13: 65-70.
25. Thomas B, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004; 1: 176-84.
26. Goossens J, Delbaere I, Van Lancker A, et al. Cancer patients’ and professional caregivers’ needs, preferences and factors associated with receiving and providing fertility-related information: a mixed-methods systematic review. Int J Nurs Studies 2014; 51: 300-19.
27. Nierop-van Baalen C, Grypdonck M, Hecke A, Verhaeghe S. Associated factors of hope in cancer patients during treatment: a systematic literature review. J Adv Nurs 2020; 76: 1520-37.
28. Ma ZY, Law WL, Ng EKO, et al. Methylated septin 9 and carcinoembryonic antigen for serological diagnosis and monitoring of patients with colorectal cancer after surgery. Sci Rep 2019; 9: 10326.
29. Toth K, Sipos F, Kalmar A, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One 2012; 7: 212-30.
30. Lu DC, Zhang QF, Li L, et al. Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study. BMC Gastroenterol 2022; 22: 232.
31. Leung WK, Shin V, Law WL. Detection of methylated septin 9 DNA in blood for diagnosis, prognosis, and surveillance of colorectal cancer. Hong Kong Med J 2019; 25: 145-52.
32. Lee H, Hwang S, Kim TS. Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol 2013; 6: 290-6.
33. Eldeeb G, Fawzy A, El‑Hefnawy S, et al. Study of the role of serum methylated septin9 in early detection of colorectal cancers in comparison with colonoscopy. Menoufia Med J 2020; 33: 824-9.
34. Sun J, Fei F, Zhang M, et al. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal Cancer. BMC Cancer 2019; 19: 450.
35. Song L, Guo S, Wang J, et al. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med 2018; 25: 152-61.
36. Fu B, Yan P, Zhang S, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers 2018; 2018: 6437104.
37. Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagnostics 2016; 12: 12-9.
38. Yuan P, Cheng X, Wu X, et al. OSMR and SEPT9: promising biomarkers for detection of colorectal cancer based on blood-based tests. Transl Cancer Res 2016; 5: 131-9.
39. Ma Z, Yan Chan C, Lau K. Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer. Sci Rep 2021; 11: 23446.
40. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
41. Rawla P, Sunkara T, Barsok A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Rev 2019; 14: 89-103.
42. Dougherty MK, Brenner AT, Crochett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta -analysis. JAMA Intern Med 2018; 178: 1645-58.
43. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening .Gastroenterology 2020; 158: 418-32.
44. Xie L, Jiang X, Li Q, et al. Diagnostic value of methylated Septin9 for colorectal cancer detection. Front Oncol 2018; 8: 247.
45. Kurreck A, Karthaus M, Fruehauf S, et al. Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: evaluation of the phase II PanaMa trial (AIO KRK 0212). J Clin Oncol 2022; 40 (16 Suppl): 3587.
46. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009; 55: 1337-46.
47. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54: 414-23.
48. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 2015; 30: 830-3.
49. Song L, Peng X, Li Y, et al. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. Epigenomics 2017; 9: 599-610.
50. Łukaszewicz-Zajac M, Mroczko B. Circulating biomarkers of colorectal cancer (CRC) – their utility in diagnosis and prognosis. J Clin Med 2021; 10: 2391-5.
51. Xie L, Jiang X, Li Q, et al. Diagnostic value of methylated septin 9 for colorectal cancer detection. Front Oncol 2018; 8: 247.
52. Potter NT, Hurban P, White MN, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem 2014; 60: 1183-91.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.